On the contrary, silencing of LRP5 suppressed the tumorigenicity and sensitized CRC to cisplatin treatment by targeting Wnt/β‐catenin mediated CSC properties and IL‐6/STAT3 pathway. The gene discussed is LRP5; the disease is colorectal carcinoma.